Early-Stage Diabetic Foot Ulcer Treatment

537

million

diabetics worldwide*

* 2021 International Diabetes Federation

107

million

15%-25% of diabetics will develop a chronic, non-healing foot ulcer**

** 2022 - 2028 Market Growth Reports "Diabetic Foot Ulcers Treatment Market..."

26

million

24% of foot ulcers progress to require lower limb amputation***

*** July 2021 "Lower Limb Amputation Rates in Patients With Diabetes and an Infected Foot Ulcer: A Prospective Observational Study"

Non-Diabetic

There is a balance between the Opioid Growth Factor (OGF) and the Opioid Growth Factor Receptor (OGFr), resulting in normal wound healing elements

Diabetic

Diabetics have a dysregulated OGF/OGFr, which suppresses key wound healing elements

  • Depressed cell migration and division

  • Decreased angiogenesis*

  • Reduced fibroblast** proliferation

  • Depressed collagen synthesis

  • Incomplete wound healing

  • Poor wound strength

Solution

Elkos' topical NTX blocks the OGFr, restoring healing at doses as low as 0.03%:

  • Reverses depressed cell replication

  • Restores Angiogenesis

  • Increases fibroblast proliferation

  • Reverses depressed collagen synthesis

  • Restores more complete wound healing

  • Results in normal tensile strength

IN THE NEWS

ElkosRX is moving towards clinical trials with their topical treatment

ElkosRx has developed an investigational treatment for diabetic foot ulcers (DFU) which, unlike the competition, targets the pathophysiology of DFUs